FDA Approves Banzel (rufinamide) as Adjunctive Treatment for Severe Epilepsy Disorder. Drug approbation.
Tuesday, November 18th, 2008A double-blind, placebo-controlled crucial ponder of LGS patients treated with Banzel as adjunctive remedy showed a 42.5 percent median reduction in frequency of decline attacks, seizures that cause a mortal to mislay consciousness and destruction to the ground, compared with a 1.4 percent median enlargement for placebo-treated patients. Drop attacks are a leading cause of offence in LGS patients.
"People living with LGS stress more remedying options," said Tracy Glauser, MD, Director, Comprehensive Epilepsy Program, Cincinnati Children's Hospital Medical Center, Ohio, and usher investigator in a clinical misery for Banzel. "What's sexy about this muse about is that Banzel was noticeable and non-specifically well tolerated in children with LGS whose seizures were heretofore ungoverned on Other multiple antiepileptic medications." LGS is a Cancer that is keen to the lives of patients and caregivers.
